I had a similar hesitance with ICU regarding the commercial potential, and this was regardless of the regulatory issues. Wondering the same here. Assuming no hiccups on the FDA approval, what is the commercial potential?
Well that is all fine on a positive result but since Ayers thinks it is only 50/50 what happens to the stock upon negative results? We won't get a chance to take profits. And since you felt the company seemed to indicate a GIA mentality this could turn out out to be a very very long hold strategy upon poor results if you only intend to sell upon good results.
Market Data 
Markets 
AI
